Video

(AAO) Medication could reduce burden of steroid drops for patients

Cynthia Matossian, MD, FACS, ABES presents the highlights of a poster on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.


Cynthia Matossian, MD, FACES, ABES, of Matossian Eye Associates, presents the highlights of a poster on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.

The study examined early experiences among cataract surgeons with the use of the injectabcle ophthalmic anti-inflammatory medications.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
© 2025 MJH Life Sciences

All rights reserved.